<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF06ABFB-9547-484C-84F9-4110ED8759B7"><gtr:id>BF06ABFB-9547-484C-84F9-4110ED8759B7</gtr:id><gtr:name>Manchester University NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Central Manchester University Hospitals NHS Foundation Trust,Manchester Royal Infirmary,Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF06ABFB-9547-484C-84F9-4110ED8759B7"><gtr:id>BF06ABFB-9547-484C-84F9-4110ED8759B7</gtr:id><gtr:name>Manchester University NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Central Manchester University Hospitals NHS Foundation Trust,Manchester Royal Infirmary,Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/01455610-6963-4E1C-8078-032704AF1277"><gtr:id>01455610-6963-4E1C-8078-032704AF1277</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Blaikley</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601556"><gtr:id>EDDAA7F2-1B6F-4C37-8E85-3609FAC436A0</gtr:id><gtr:title>Glucocorticoid regulation of interleukin 8 expression in chronic obstructive pulmonary disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0601556</gtr:grantReference><gtr:abstractText>Chronic obstructive pulmonary disease (COPD) is an inflammatory lung condition and a major cause of deaths worldwide. Since it is an inflammatory disease antiinflamatory medication such as steroids should be effective. However steroids usually fail to improve the COPD disease course significantly. This clinically observed resistance to steroid treatment is likely to be important for understanding the basis of the disease itself, and also for the clinical management of patients.
We are, therefore, currently investigating steroid action in COPD. We are doing this by comparing inflammatory lung cells between COPD patients and healthy volunteers. Interleukin 8 is a critical signal for recruitment of inflammatory cells to the lung, and is expressed at high level in COPD. Interleukin 8 is typically inhibited by glucocorticoids; but this effect is lost in COPD, contributing to their lack of beneficial effect. We will discover why interleukin 8, in COPD, acquires resistance to glucocorticoid inhibition. This will indicate new approaches to COPD treatment.</gtr:abstractText><gtr:technicalSummary>Background: Chronic obstructive pulmonary disease (COPD) is a major cause of premature death, and morbidity throughout the world. The disease is generally resistant to glucocorticoids (GC). Alveolar macrophages appear to have a central role, attracting neutrophils and lymphocytes. COPD encompasses many different phenotypes. A high sputum eosinophil count is associated with better glucocorticoid response therefore defining a particular disease phenotype. Interleukin 8 production by airway macrophages is constitutively high, and resistant to inhibition by GC, whereas peripheral blood derived macrophages respond to both stimulation with lipopolysaccharide (LPS), and inhibition with GC. 

Aim: To define the basis for the constitutively high expression of IL-8. 

Design: I will recruit patients with COPD, either with high sputum eosinophil counts or low eosinophil counts. Airway macrophages will be harvested at bronchoscopy, with airway mucosal biopsies. 

Objective 1: I will define ex-vivo cytokine responses to stimulation with LPS, and inhibition with GC, p38 kinase or both. A limited immunohistochemical study will then be done using previously optimised antibodies to cells. 

Objective 2: Using celltracker software and confocal microscopy I will measure expression, and activation of the glucocorticoid receptor (GR). I will also track p38 and NFkB. I will determine protein expression in conditions of LPS activation, p38 inhibition, GC treatment and inhibition with both p38 and GC. 

Objective 3: Using a new form of chromatin immunoprecipitation. I will examine the IL8 gene architecture, and transcription factor binding. I will compare lung with peripheral blood derived cells, and will use the TNF gene, which is repressed by GC under the same conditions, as a further control.

Scientific and Medical Opportunities: I will define why IL8 is not repressed by GC therefore suggesting new therapeutic approaches. I will also be able to use p38 inhibitors, which are in early clinical trials, to investigate the role of this kinase in modulating GC action.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-02</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>223442</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Industry sponsorship</gtr:description><gtr:id>AB919C51-3591-4700-9678-1AFD190DF9BF</gtr:id><gtr:impact>The ligands have enabled us to gain two NIHR awards.
The access to the ligands also was a key part of my clinician scientist application.

Two papers:
1) Optimised chemical probes for REVERBalpha J Med Chem
2) The nuclear receptor REV-ERBa mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. PNAS</gtr:impact><gtr:outcomeId>8D8CF108251-1</gtr:outcomeId><gtr:partnerContribution>GSK developed novel ligands and synthesised them, allowing us to use them in our investigations.</gtr:partnerContribution><gtr:piContribution>We provided preliminary data showing that a clock protein, REVERBalpha, regulated the immune system. We were able to investigate the accuracy of the ligands targetting REVERB alpha in primary cells suggesting their translational importance.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lung transplant lectureship</gtr:description><gtr:id>0D2F2926-FE7E-43DB-BAE6-2CA83E913DF3</gtr:id><gtr:impact>Three sets of peer reviewed funding came from my time in the department (Clinical lectureship grant, SFE early career grant and a MRC clinician scientist award)</gtr:impact><gtr:outcomeId>f4icwm3C1Ag-1</gtr:outcomeId><gtr:partnerContribution>My partners allowed me to gain samples whilst in the department.</gtr:partnerContribution><gtr:piContribution>From my clinical research fellowship I was able to successfully apply for a clinical lectureship gaining data for my intermediate fellowship application</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British thoracic society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>26913E86-B587-4F35-8EBD-87F687EBA60B</gtr:id><gtr:impact>I presented my data concerning the function of reverb alpha in macrophages whilst being awarded the BTS young investigator of the year.

Rev-erba, a novel anti-inflammatory target, modifies the circadian oscillation of pulmonary inflammation
J Blaikley, L Green, J Gibbs, S Farrow, A Loudon, D Singh, D Ray


This raised my profile within the respiratory community allowing me to set up national and international collaborations to support my clinician scientist application</gtr:impact><gtr:outcomeId>ZUKa5umpus6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://thorax.bmj.com/content/65/Suppl_4/A1.1.abstract</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European respiratory society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C8E2A13B-43F3-4635-A025-2E899997A56F</gtr:id><gtr:impact>European respiratory society

Reverba is a novel regulator of COPD macrophage inflammation and glucocorticoid resistance J. Blaikley, J. Gibbs, A. Loudon, S. Farrow, D. Singh, D. Ray

Interest was generated in clocks and this lead to future collaborations that otherwise would not have been possible</gtr:impact><gtr:outcomeId>ibRXqDsPzYY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>https://www.ersnetsecure.org/public/prg_congres.detail?ww_i_session=17878&amp;ww_c_mode=TEXTE-SPECIAL</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Toronto University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F40B7588-7B9D-4453-B3C3-1992D15B688B</gtr:id><gtr:impact>The talk sparked interest in biological timing mechanisms

Collaboration with Richard Horner</gtr:impact><gtr:outcomeId>5460cc7b7fe478.67018438</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>8500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Manchester Musculoskeletal Biomedical Research Unit</gtr:department><gtr:description>Biomedical research centre microarray award</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>FA7F4751-65D7-45CA-A889-C458AA67C6AC</gtr:id><gtr:outcomeId>88869A049400</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Early career grant</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Society for Endocrinology</gtr:fundingOrg><gtr:id>A3F7F277-82BA-41F6-A4AA-654F07BC79EA</gtr:id><gtr:outcomeId>oqyTp82cJqY</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1007966</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC clinician scientist award</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CA1CBDE2-EB28-4A38-A0FC-D786B3252A7E</gtr:id><gtr:outcomeId>GXWELmiXWAC</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Eureopean Respiratory Society COPD travel award</gtr:description><gtr:fundingOrg>European Respiratory Society (ERS)</gtr:fundingOrg><gtr:id>9CFC75EA-1F74-4828-853C-2427EC06C2E7</gtr:id><gtr:outcomeId>jUUUAdanMak0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1102534</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>clinician scientist</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DFC001EA-3463-4286-9EB7-7ABB7E1B88F8</gtr:id><gtr:outcomeId>58b9aadd657c75.42665890</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28269</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical lecturer starter grant</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>66D97856-027B-4AE3-B694-8B0D69EC1A62</gtr:id><gtr:outcomeId>iCRKrvTpqSb</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PUMP priming award for new technology</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>B8ABB47C-A5F8-42E9-8EBA-E3BBCED3D463</gtr:id><gtr:outcomeId>CAEF7343EBC0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>THP-1 cell line in which the clock protein REVERBalpha was knocked down using shRNA.</gtr:description><gtr:id>6A98DC06-F65A-4ABB-90B7-9A9C1FAF761A</gtr:id><gtr:impact>Allowed us to confirm that IL-6 is regulated by REVERBalpha and this was subsequently published in a PNAS paper.</gtr:impact><gtr:outcomeId>assgUyufpVQ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>THP-1 knockdown cells in which a clock protein has been knocked down</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2022650C-477D-4FA6-BFE7-35B914D5A3D8</gtr:id><gtr:title>Management of peripheral lymph node tuberculosis in routine practice: an unselected 10-year cohort.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3984398333ebf4ba9083d47291bc2c46"><gtr:id>3984398333ebf4ba9083d47291bc2c46</gtr:id><gtr:otherNames>Blaikley JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>pm_12859_29_21333106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CAA8029-0275-4CAC-A23F-E096184E7AE0</gtr:id><gtr:title>The nuclear receptor REV-ERBa mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00f5923ffee9481b9e8547d3333ac901"><gtr:id>00f5923ffee9481b9e8547d3333ac901</gtr:id><gtr:otherNames>Gibbs JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_12859_29_22184247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1DD6082-1B13-475B-A4D9-48FB92ED9135</gtr:id><gtr:title>Increased airway T regulatory cells in asthmatic subjects.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0473de90b336ae6f14a53307a1b19656"><gtr:id>0473de90b336ae6f14a53307a1b19656</gtr:id><gtr:otherNames>Smyth LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>pm_12859_29_20453071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44335F52-BB66-4ADE-97B5-6BB82176D85B</gtr:id><gtr:title>A matter of time: study of circadian clocks and their role in inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f27aac886052288574ed14759f180b4"><gtr:id>8f27aac886052288574ed14759f180b4</gtr:id><gtr:otherNames>Carter SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>58b9a52a265e27.13668577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>596CECD1-4EA3-4359-B77B-58251D96AAAB</gtr:id><gtr:title>Optimized chemical probes for REV-ERBa.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/feae7a04a53e4ff27655841c7c542127"><gtr:id>feae7a04a53e4ff27655841c7c542127</gtr:id><gtr:otherNames>Trump RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_12859_29_23656296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>677C6B54-C30D-4E7C-AD85-8D9BB37F5DE4</gtr:id><gtr:title>Familial glucocorticoid resistance caused by a novel frameshift glucocorticoid receptor mutation.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72ce38b5f9a12469bf171b0af801551a"><gtr:id>72ce38b5f9a12469bf171b0af801551a</gtr:id><gtr:otherNames>Trebble P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>asT8GYE8LEN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20BCD7A5-B0BD-42D9-9B48-F60CCA35F9C0</gtr:id><gtr:title>Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9db6fe32602eeaa270861c625b97df72"><gtr:id>9db6fe32602eeaa270861c625b97df72</gtr:id><gtr:otherNames>Plumb J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12859_29_23704983</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601556</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>